We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+1.08%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$335M
AUM Growth
+$128M
(+62%)
Cap. Flow
+$125M
Cap. Flow
% of AUM
37.46%
Top 10 Holdings %
Top 10 Hldgs %
47.51%
Holding
207
New
53
Increased
79
Reduced
42
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$23.4M |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$12M |
| 3 |
ETP
Energy Transfer Partners L.p.
ETP
|
+$7.84M |
| 4 |
WPZ
Williams Partners L.P.
WPZ
|
+$6.77M |
| 5 |
EEP
Enbridge Energy Partners
EEP
|
+$5.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.69M |
| 2 |
Williams Companies
WMB
|
+$1.69M |
| 3 |
ProShares Ultra 20+ Year Treasury
UBT
|
+$1.24M |
| 4 |
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
|
+$1.02M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
+$989K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 57.29% |
| 2 | Healthcare | 12.14% |
| 3 | Utilities | 3.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Enanta Pharmaceuticals
ENTA
$372M
| $985K | 0.29% |
29,394
+2,745
| +10% | +$78.7K |
|
52
iShares US Real Estate ETF
IYR
$4.59B
| $978K | 0.29% |
+12,711
| New | +$966K |
|
|
ICPT
53
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $975K | 0.29% |
8,971
+4,593
| +105% | +$547K |
|
|
KERX
54
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $974K | 0.29% |
166,223
+60,346
| +57% | +$330K |
|
|
TSRO
55
DELISTED
TESARO, Inc.
TSRO
| $973K | 0.29% |
7,233
-7,844
| -52% | -$989K |
|
56
United Therapeutics
UTHR
$26.3B
| $972K | 0.29% |
6,777
+973
| +17% | +$124K |
|
57
Theravance Biopharma
TBPH
$874M
| $964K | 0.29% |
30,237
+2,408
| +9% | +$74.7K |
|
58
DTE Energy
DTE
$31.1B
| $960K | 0.29% |
+11,452
| New | +$921K |
|
59
Ionis Pharmaceuticals
IONS
$9.35B
| $946K | 0.28% |
19,777
-8,079
| -29% | -$320K |
|
60
State Street SPDR Bloomberg Convertible Securities ETF
CWB
$5.64B
| $943K | 0.28% |
+20,659
| New | +$943K |
|
61
Nektar Therapeutics
NKTR
$2.39B
| $943K | 0.28% |
5,122
+2,364
| +86% | +$481K |
|
|
CELG
62
DELISTED
Celgene Corp
CELG
| $935K | 0.28% |
8,081
+1,919
| +31% | +$214K |
|
63
Vanda Pharmaceuticals
VNDA
$312M
| $933K | 0.28% |
58,490
+954
| +2% | +$15.3K |
|
|
ARIA
64
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $929K | 0.28% |
74,688
-957
| -1% | -$11.5K |
|
65
Biogen
BIIB
$29.9B
| $927K | 0.28% |
3,269
+694
| +27% | +$206K |
|
66
Incyte
INCY
$23.5B
| $916K | 0.27% |
9,137
+1,333
| +17% | +$130K |
|
67
Ironwood Pharmaceuticals
IRWD
$611M
| $914K | 0.27% |
71,399
+13,643
| +24% | +$172K |
|
68
BioMarin Pharmaceuticals
BMRN
$11.5B
| $906K | 0.27% |
10,935
+3,254
| +42% | +$280K |
|
69
Omeros
OMER
$709M
| $901K | 0.27% |
90,858
+34,922
| +62% | +$356K |
|
70
Regeneron Pharmaceuticals
REGN
$68.8B
| $900K | 0.27% |
2,453
+755
| +44% | +$287K |
|
|
PGNX
71
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $900K | 0.27% |
104,213
-31,127
| -23% | -$230K |
|
72
Gilead Sciences
GILD
$161B
| $885K | 0.26% |
12,361
+4,911
| +66% | +$365K |
|
73
Ligand Pharmaceuticals
LGND
$6.02B
| $885K | 0.26% |
13,969
+5,342
| +62% | +$337K |
|
74
Travere Therapeutics
TVTX
$5.33B
| $883K | 0.26% |
46,654
+9,061
| +24% | +$185K |
|
75
Vertex Pharmaceuticals
VRTX
$121B
| $880K | 0.26% |
11,947
+5,133
| +75% | +$418K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q4 2016 Portfolio in Review
As of Q4 2016, Virtus ETF Advisers held 207 positions worth $335M, up 62% from $207M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Virtus ETF Advisers deployed $125M of net new capital in Q4 2016, opening 53 new positions and adding to 79 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 107,222 shares worth $24M.
By sector, the portfolio is most concentrated in Energy at 57% of assets, down from 64% a quarter earlier, followed by Healthcare and Utilities.
On the sell side, the largest reduction was Williams Companies, an estimated $1.69M trimmed.
- Virtus ETF Advisers's largest Q4 2016 buy was State Street SPDR S&P 500 ETF Trust: 107,222 shares worth $24M.
- Virtus ETF Advisers added most to Energy Transfer Partners L.p. in Q4 2016, an estimated $7.84M increase.
- Virtus ETF Advisers's biggest Q4 2016 reduction was Williams Companies, cutting an estimated $1.69M.
- Virtus ETF Advisers fully exited iShares 20+ Year Treasury Bond ETF in Q4 2016, selling an estimated $1.69M.
- Virtus ETF Advisers's ten largest holdings make up 48% of its $335M portfolio in Q4 2016.
- Virtus ETF Advisers opened 53 new positions and closed 32 in Q4 2016.
- Virtus ETF Advisers's portfolio value rose 62% quarter-over-quarter to $335M.
Based on Virtus ETF Advisers's 13F filing for Q4 2016, filed 14 Feb 2017.